FAT1 and acute myeloid leukemia: Clinical studies have also found that FAT1 mutations may be associated with poor outcomes and relapse in normal karyotype AML patients undergoing allogeneic hematopoietic cell transplantation (HCT), suggesting that FAT1 could be a pathogenic driver in AML (26).